UPSTAND: A Study of the Change in Early and Sustained Pain Control in Radiographic Axial Spondylarthritis in Adult Participants Receiving Upadacitinib
Study Details
Study Description
Brief Summary
Axial spondyloarthritis (axSpA) is an immune-mediated inflammatory disease primarily affecting the axial skeleton. The most frequent axSpA symptom is chronic, often inflammatory back pain (IBP) that might be difficult to distinguish from other causes of chronic back pain (CBP). Many participants report persistent pain, including back pain, which impacts disease activity and quality of life including creating burdens such as sleep disturbance, social isolation, loss of productivity, as well as anxiety and depression. Despite this, there is a lack of detailed data and knowledge on pain in radiographic-axial spondyloarthritis (r-axSpA), including pain types, how it is localized, and how these different facets of pain are impacted by treatment. This study will assess the real-world effectiveness of upadacitinib on early and sustained pain control, and the association between pain and clinical/patient-reported outcomes in radiographic axSpA participants.
Upadacitinib is being developed for the treatment of r-axSpA. Approximately 877 adult participants with activer-axSpA will be enrolled across approximately 19 countries in Europe, North America, South America, and Asia-Pacific.
Participants will receive oral upadacitinib tablets as prescribed by the physician prior to enrolling in this study in accordance with the terms of the local marketing authorization and professional and reimbursement guidelines with regards to dose, population and indication. The overall duration of the study is approximately 30 months.
There may be a higher burden for participants in this study compared to usual standard of care. Participants will attend regular visits per routine clinical practice. The effect of the treatment will be checked by medical assessments, checking for side effects, and questionnaires.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
|
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Participants Receiving Upadacitinib Participants receiving Upadacitinib for radiographic axial spondyloarthritis (r-axSpA). |
Outcome Measures
Primary Outcome Measures
- Percentage of Participants with a Total Spinal Pain Score < 4 and >= 2 Unit (0 - 10) Improvement [Baseline (Week 0) to Week 12]
Total spinal pain consists of the mean of two 0-10 numerical rating scale (NRS) questions: total back pain during the previous week and nocturnal back pain during the previous week.
- Percentage of Participants Maintaining Total Spinal Pain < 4 Among Participants Who Achieved Total Spinal Pain < 4 and >= 2 unit (0 - 10) Improvement from Baseline at Week 12 [Week 52]
Total spinal pain score consists of the mean of two 0-10 NRS questions: total back pain during the previous week and nocturnal back pain during the previous week.
Secondary Outcome Measures
- Change in Participant's Assessment of Total Spinal Pain [Baseline to Week 52]
Total spinal pain consists of the mean of two 0-10 NRS questions: total back pain during the previous week and nocturnal back pain during the previous week.
- Change in Patient's Assessment of Total Back Pain NRS [Baseline (Week 0) to Week 52]
Pain will be measured using a 0 - 10 numerical rating scale (NRS) for total back pain (0 = no pain and 10 = most severe pain).
- Change in Patient's Assessment of Nocturnal Back Pain NRS [Baseline (Week 0) to Week 52]
Pain will be measured using a 0 - 10 numerical rating scale (NRS) for nocturnal back pain (0 = no pain and 10 = most severe pain).
- Change in painDETECT Questionnaire (PD-Q) Score [Baseline (Week 0) to Week 52]
The PD-Q is a patient-based questionnaire used to determine the prevalence of neuropathic pain components in low back pain participants. Scores range from -1 to 38, with higher scores indicating a greater likelihood of the participant's pain having a neuropathic component.
- Change in Widespread Pain Index (WPI) [Baseline (Week 0) to Week 52]
The WPI quantifies the extent of bodily pain on a 0 to 19 scale by asking participants if they have had pain or tenderness in 19 different body regions (shoulder girdle, hip, jaw, upper arm, upper leg, lower arm, and lower leg on each side of the body, as well as upper back, lower back, chest, neck, and abdomen) over the past week, with each painful or tender region scoring 1 point.
- Percentage of Participants Achieving Pittsburgh Sleep Quality Index (PSQI) score < 5 [Up to Week 52]
The PSQI consists of 19 individual items across 7 components: sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleep medications, and daytime dysfunction. Each component is scored from 0 (no difficulty) to 3 (severe difficulty) and summed to produce a total global score (range 0 to 21). A score of less than 5 is indicative of no clinical sleep impairment
- Percentage of Participants Achieving Ankylosing Spondylitis Disease Activity Score Low Disease Activity .[ASDAS LDA (< 2.1)] [Up to Week 52]
The ASDAS combines the following 5 disease activity variables: back pain (BASDAI Question 2 NRS score 0 - 10), peripheral pain/swelling (BASDAI Question 3 NRS score 0 - 10), duration of morning stiffness (BASDAI Question 6 NRS score 0 - 10), PtGA, and high-sensitivity c reactive protein (hsCRP) or erythrocyte sedimentation rate (ESR). Low disease is defined as an ASDAS < 2.1.
- Percentage of Participants Achieving Ankylosing Spondylitis Disease Activity Score Inactive Disease [ASDAS ID (<1.3)] [Up to Week 52]
The ASDAS combines the following 5 disease activity variables: back pain (BASDAI Question 2 NRS score 0 - 10), peripheral pain/swelling (BASDAI Question 3 NRS score 0 - 10), duration of morning stiffness (BASDAI Question 6 NRS score 0 - 10), PtGA, and high-sensitivity c reactive protein (hsCRP) or erythrocyte sedimentation rate (ESR). Inactive disease is defined as an ASDAS < 1.3.
- Change in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) [Baseline (Week 0) to Week 52]
The BASDAI consists of 6 questions on a 0 to 10 NRS (0 being no problem and 10 being very severe problems) pertaining to the 5 major symptoms of r-axSpA: fatigue, spinal pain, peripheral joint pain/swelling, areas of localized tenderness (also called enthesitis, or inflammation of tendons and ligaments), morning stiffness duration, and morning stiffness severity. The overall BASDAI score ranges from 0 to 10, with higher scores indicating greater disease activity.
- Change in 12-Item Short Form Health Survey (SF-12) Physical Component Summary (PCS) [Baseline (Week 0) to Week 52]
The SF-12 is a generic health-related QoL instrument consisting of a subset of 12 questions from the 36-Item Short Form Health Survey (SF-36). It assesses quality of life (QoL) across 8 domains: physical functioning, role physical, role emotional, social functioning, bodily pain, vitality, mental health, and general health. The SF-12 is used to derive the PCS with higher scores indicating a higher QoL.
- Change in 12-Item Short Form Health Survey (SF-12) Mental Component Summary (MCS) [Baseline (Week 0) to Week 52]
The SF-12 is a generic health-related QoL instrument consisting of a subset of 12 questions from the 36-Item Short Form Health Survey (SF-36). It assesses quality of life (QoL) across 8 domains: physical functioning, role physical, role emotional, social functioning, bodily pain, vitality, mental health, and general health. The SF-12 is used to derive the MCS with higher scores indicating a higher QoL.
- Percentage of Participants Achieving [Hospital Anxiety and Depression Scale (HADS) score <= 7] for a participants with HADS score > 7 at Baseline [Up to Week 52]
The HADS assesses participant mental health status (consists of anxiety [Hospital Anxiety and Depression Scale-Anxiety (HADS-A)] and depression [Hospital Anxiety and Depression Scale-Depression (HADS-D)] subscales). The range for both subscales is 0 - 21, with 0 - 7 = normal, 8 - 10 = borderline abnormal, and 11 - 21 = abnormal.
- Change in Bath Ankylosing Spondylitis Functional Index (BASFI) [Baseline (Week 0) to Week 52]
The BASFI is a validated patient-reported outcome (PRO) instrument for use in the r-axSpA participant population. It consists of 10 items measured on a 0 to 10 NRS, which assesses the ability to perform activities known to be problematic to r-axSpA patients such as dressing, bending, reaching, turning, and climbing steps. The total scores range from 0 to 10 with higher scores indicating worse physical functioning in r-axSpA participants.
- Change in ASDAS [Baseline (Week 0) to Week 52]
The ASDAS combines the following 5 disease activity variables: back pain (BASDAI Question 2 NRS score 0 - 10), peripheral pain/swelling (BASDAI Question 3 NRS score 0 - 10), duration of morning stiffness (BASDAI Question 6 NRS score 0 - 10), PtGA, and high-sensitivity c reactive protein (hsCRP) or erythrocyte sedimentation rate (ESR).
- Change in C-Reactive Protein (CRP) [Baseline (Week 0) to Week 52]
Change in CRP.
- Percentage of Participants with Discontinuation of Nonsteroidal Anti-Inflammatory Drug (NSAID) Among Participants using NSAIDs at Baseline [Up to Week 52]
Discontinuation of NSAID among participants using NSAIDs at Baseline.
- Percentage of Participants using NSAIDs as Needed or Continuously [Baseline (Week 0) to Week 52]
Percentage of participants using NSAIDs as needed or continuously.
- Change in Total Daily Dose of NSAIDs [Baseline (Week 0) to Week 52]
Change in total daily dose of NSAIDs.
- Percentage of Participants Achieving Enthesitis Resolution [Maastricht Ankylosing Spondylitis Enthesitis Score (MASES = 0)] among Participants with any Enthesitis (MASES ≥ 1) at Baseline [Baseline (Week 0) to Week 52]
The MASES evaluates the presence or absence of enthesitis at 13 different sites (first costochondral joint left/right, seventh costochondral joint left/right, posterior superior iliac spine left/right, anterior superior iliac spine left/right, iliac crest left/right, fifth lumbar spinous process, and proximal insertion of Achilles tendon left/right).
- Percentage of Participants with New Onset of Extra-articular Manifestations (EAMs) Among Participants with no History of EAMs [Up to Week 52]
Percentage of participants with new onset for participants with no history of EAMs (e.g., uveitis and inflammatory bowel disease [IBD]).
- Percentage of Participants with Recurrence of EAMs among Participants with Previous History of EAMs [Up to Week 52]
Percentage of participants with recurrence for participants with previous history of EAMs (e.g., uveitis and IBD).
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Clinical diagnosis of Radiographic Axial Spondylarthritis (r-axSpA) and meeting the modified New York Criteria for r-axSpA.
-
Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score ≥ 4 at Baseline.
-
Total back pain score ≥ 4 at Baseline.
-
Inadequate response to at least two nonsteroidal anti-inflammatory drugs (NSAIDs) over an at least 4-week period in total at maximum recommended or tolerated doses, or participant has an intolerance to contraindication for NSAIDs as defined by the investigator.
-
Upadacitinib prescribed in accordance with the applicable approved label and local regulatory and reimbursement policies.
Exclusion Criteria:
-
Prior exposure to any Janus kinase (JAK) inhibitor.
-
Participants demonstrating active symptoms of fibromyalgia as per clinical diagnosis.
-
Participation in a clinical trial of an investigational drug, concurrently or within the last 30 days.
-
Unwillingness or inability to comply with the study requirements, including completion of patient reported outcome questionnaires.
-
Participants who cannot be treated with upadacitinib according to the applicable approved label (e.g., contraindications).
-
Vulnerable or protected adult patients with lack of capability to give informed consent.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Hospital Italiano La Plata /ID# 230779 | La Plata | Buenos Aires | Argentina | 1902 |
| 2 | CER Instituto Medico /ID# 230782 | Quilmes | Buenos Aires | Argentina | 1878 |
| 3 | Instituto CAICI /ID# 230781 | Rosario | Santa Fe | Argentina | 2000 |
| 4 | Clinica Regional del Sud /ID# 248866 | Rio Cuarto | Argentina | 5800 | |
| 5 | Cimer /Id# 230780 | San Miguel de Tucuman | Argentina | 4000 | |
| 6 | Paratus Clinical /ID# 231460 | Phillip | Australian Capital Territory | Australia | 2606 |
| 7 | Genesis Research Services /ID# 231593 | Broadmeadow | New South Wales | Australia | 2292 |
| 8 | Campbelltown Hospital /ID# 231462 | Campbelltown | New South Wales | Australia | 2560 |
| 9 | Royal Prince Alfred Hospital /ID# 232417 | Camperdown | New South Wales | Australia | 2050 |
| 10 | BJC Health /ID# 230066 | Paramatta | New South Wales | Australia | 2150 |
| 11 | Barwon Rheumatology Services /ID# 230068 | Geelong | Victoria | Australia | 3220 |
| 12 | Peninsula Rheumatology /ID# 240172 | Langwarrin | Victoria | Australia | 3910 |
| 13 | Joint West Rheumatology /ID# 231461 | Murdoch | Western Australia | Australia | 6150 |
| 14 | Cliniques Universitaires de Bruxelles Hopital Erasme /ID# 238961 | Brussels | Bruxelles-Capitale | Belgium | 1070 |
| 15 | Rhumaconsult SPRL /ID# 231439 | Charleroi | Hainaut | Belgium | 6000 |
| 16 | Onze Lieve Vrouw Hospital /ID# 238963 | Aalst | Belgium | 9300 | |
| 17 | AZ Sint-Jan Brugge /ID# 238964 | Brugge | Belgium | 8000 | |
| 18 | CHU Brugmann /ID# 238962 | Bruxelles | Belgium | 1020 | |
| 19 | Reumacentrum /ID# 231437 | Genk | Belgium | 3600 | |
| 20 | ReumaClinic /ID# 231438 | Genk | Belgium | 3600 | |
| 21 | Centre Hospitalier Universitaire du Sart Tilman CHU de Liege /ID# 231440 | Liege | Belgium | 4000 | |
| 22 | AZ Damiaan /ID# 231441 | Oostende | Belgium | 8400 | |
| 23 | AZ-Delta /ID# 238966 | Roeselare | Belgium | 8800 | |
| 24 | UMHAT Kaspela EOOD /ID# 249621 | Plovdiv | Bulgaria | 4001 | |
| 25 | Medical center Unimed /ID# 249618 | Plovdiv | Bulgaria | 4023 | |
| 26 | Diagnostic consultative center 17 Sofia /ID# 249620 | Sofia | Bulgaria | 1505 | |
| 27 | Military Medical Academy Multiprofile Hospital /ID# 249623 | Sofia | Bulgaria | 1606 | |
| 28 | Artus Health Center /ID# 241966 | Vancouver | British Columbia | Canada | V5Z 1J9 |
| 29 | Manitoba Clinic /ID# 246217 | Winnipeg | Manitoba | Canada | R3A 1M3 |
| 30 | CIADS Research Co Ltd /ID# 247520 | Winnipeg | Manitoba | Canada | R3N 0K6 |
| 31 | Dr. Juris Lazovskis Inc. /ID# 246574 | Sydney | Nova Scotia | Canada | B1S 3N1 |
| 32 | The Waterside Clinic /ID# 248678 | Barrie | Ontario | Canada | L4M 6L2 |
| 33 | Dr. Chrisostomos Kouroukis & Dr. Pauline Boulos MPC /ID# 246213 | Dundas | Ontario | Canada | L9H 1B7 |
| 34 | Arthur Karasik Medicine Professional Corporation /ID# 241932 | Etobicoke | Ontario | Canada | M9C 5N2 |
| 35 | Lau Bacchus Professional Medicine Corp /ID# 242591 | Hamilton | Ontario | Canada | L8N 1Y2 |
| 36 | Credit Valley Rheumatology /ID# 241948 | Mississauga | Ontario | Canada | L5M 2V8 |
| 37 | Dr. Sabeen Anwar Medicine Professional Corporation /ID# 241933 | Windsor | Ontario | Canada | N8X 1T3 |
| 38 | Applied Medical Informatics Research Inc. (AMIR) /ID# 246284 | Montréal | Quebec | Canada | H4A 3T2 |
| 39 | Groupe de Recherche en Maladies Osseuses Inc /ID# 241111 | Sainte-foy | Quebec | Canada | G1V 3M7 |
| 40 | CIUSSS de l'Estrie - CHUS /ID# 247572 | Sherbrooke | Quebec | Canada | J1G 2E8 |
| 41 | Dr. Latha Naik /ID# 246516 | Saskatoon | Saskatchewan | Canada | S7K 3H3 |
| 42 | HCL - Hôpital Lyon Sud /ID# 228819 | Pierre Benite CEDEX | Auvergne-Rhone-Alpes | France | 69495 |
| 43 | CHR Orleans - Hopital de la Source /ID# 234258 | Orleans CEDEX 2 | Centre-Val De Loire | France | 45067 |
| 44 | CHU de Besancon - Jean Minjoz /ID# 230528 | Besancon | Doubs | France | 25030 |
| 45 | CHU de Besancon - Jean Minjoz /ID# 242499 | Besancon | Doubs | France | 25030 |
| 46 | CHU Limoges - Dupuytren 1 /ID# 229094 | Limoges CEDEX 1 | Franche-Comte | France | 87042 |
| 47 | CHU Toulouse - Hopital Purpan /ID# 228818 | TOULOUSE Cedex 9 | Haute-Garonne | France | 31059 |
| 48 | CHU Montpellier - Hôpital Saint Eloi /ID# 228829 | Montpellier Cedex 5 | Herault | France | 34295 |
| 49 | CHU Montpellier - Hôpital Saint Eloi /ID# 240980 | Montpellier Cedex 5 | Herault | France | 34295 |
| 50 | CHU de SAINT ETIENNE - Hopital Nord /ID# 228836 | St. Priest En Jarez | Loire | France | 42270 |
| 51 | CHU Nice -Hopital Pasteur /ID# 229088 | Nice CEDEX 1 | Provence-Alpes-Cote-d Azur | France | 06002 |
| 52 | CHU Amiens-Picardie Site Sud /ID# 228821 | Amiens CEDEX 1 | Somme | France | 80054 |
| 53 | CH du Pays d'AIX /ID# 229095 | Aix En Provence Cedex 1 | France | 13616 | |
| 54 | Centre Hospitalier d'Arras /ID# 228833 | Arras | France | 62022 | |
| 55 | CHU Bordeaux - Hopital Pellegrin /ID# 230548 | Bordeaux | France | 33000 | |
| 56 | Infirmerie Protestante /ID# 228794 | Caluire Et Cuire | France | 69300 | |
| 57 | CHU Gabriel Montpied /ID# 229092 | Clermont Ferrand | France | 63000 | |
| 58 | C. H. Sud Francilien /ID# 228826 | Corbeil Essonnes | France | 91106 | |
| 59 | CHD Vendée- La Roche-sur-Yon - Les Oudairies /ID# 230947 | La Roche Sur Yon | France | 85000 | |
| 60 | CHU Grenoble - Hopital Michallon /ID# 228792 | La Tronche | France | 38700 | |
| 61 | CHU Lille - Hôpital Roger Salengro /ID# 228820 | Lille | France | 59037 | |
| 62 | Clinique de la Sauvegarde /ID# 229087 | Lyon | France | 69009 | |
| 63 | AP-HM - Hopital Sainte Marguerite /ID# 241024 | Marseille | France | 13009 | |
| 64 | Cabinet de rhumatologie /ID# 229091 | Mennecy | France | 91540 | |
| 65 | CH Princesse Grace /ID# 228796 | Monaco | France | 98000 | |
| 66 | AP-HP - Hopital Saint-Antoine /ID# 228795 | Paris | France | 75012 | |
| 67 | Hopital Pitie Salpetriere /ID# 243309 | Paris | France | 75013 | |
| 68 | Centre de Soins Osteoarticulaires Ambulatoires /ID# 244737 | Paris | France | 75015 | |
| 69 | AP-HP - Hopital Bichat - Claude-Bernard /ID# 228837 | Paris | France | 75018 | |
| 70 | GH Diaconesses Croix Saint-Simon /ID# 238548 | Paris | France | 75020 | |
| 71 | Polyclinique Courlancy /ID# 229093 | Reims | France | 51100 | |
| 72 | CHU de Rennes - Hospital Sud /ID# 228842 | Rennes CEDEX 2 | France | 35203 | |
| 73 | Hôpital Charles-Nicolle /ID# 229096 | Rouen | France | 76000 | |
| 74 | Hôpital d'instruction des armées Bégin /ID# 228793 | Saint-Mandé cedex | France | 94163 | |
| 75 | CH Saint Nazaire /ID# 233186 | St Nazaire | France | 44600 | |
| 76 | General Hospital of Athens Ippokratio /ID# 241133 | Athens | Attiki | Greece | 11527 |
| 77 | General Hospital of Athens Laiko /ID# 241128 | Athens | Attiki | Greece | 11527 |
| 78 | University General Hospital of Heraklion PA.G.N.I /ID# 241124 | Heraklion | Kriti | Greece | 71500 |
| 79 | 424 General MILITARY Hospital /ID# 241127 | Efkarpia (Thessalonikis) | Thessaloniki | Greece | 56429 |
| 80 | Naval Hospital of Athens /ID# 241129 | Athens | Greece | 11521 | |
| 81 | KAT Atttica General Hospital /ID# 243063 | Athens | Greece | 14561 | |
| 82 | Vougiouklakeio S.A. /ID# 246476 | Egaleo | Greece | 12242 | |
| 83 | Iaso /ID# 245137 | Maroussi | Greece | 15123 | |
| 84 | University General Hospital of Patras /ID# 243795 | RION Patras Achaia | Greece | 26504 | |
| 85 | Euromedica Blue Cross Gen Clin /ID# 244945 | Thessaloniki | Greece | 54636 | |
| 86 | General Hospital of Thessaloniki Hippokrateio /ID# 243796 | Thessaloniki | Greece | 54642 | |
| 87 | Euromedica General Clinic /ID# 241126 | Thessaloniki | Greece | 54645 | |
| 88 | Debreceni Egyetem Klinikai Kozpont /ID# 239936 | Debrecen | Hajdu-Bihar | Hungary | 4032 |
| 89 | Magyar Honvedseg Egeszsegugyi Kozpont /ID# 239939 | Budapest | Hungary | 1134 | |
| 90 | Debreceni Egyetem Kenezy Gyula Egyetemi Korhaz /ID# 239937 | Debrecen | Hungary | 4031 | |
| 91 | Hevizgyogyfurdo es Szent Andras Reumakorhaz /ID# 239940 | Heviz | Hungary | 8380 | |
| 92 | Bács-Kiskun Megyei Kórház Szegedi Tudományegyetem AOK Oktató Kórháza /ID# 239938 | Kecskemet | Hungary | 6000 | |
| 93 | The Chaim Sheba Medical Center /ID# 241305 | Ramat Gan | Tel-Aviv | Israel | 5265601 |
| 94 | Tel Aviv Sourasky Medical Center /ID# 241864 | Tel Aviv-Yafo | Tel-Aviv | Israel | 6423906 |
| 95 | Hillel Yaffe Medical Center /ID# 241869 | Hadera | Israel | 38100 | |
| 96 | Bnai Zion Medical Center /ID# 241866 | Haifa | Israel | 3339419 | |
| 97 | The Lady Davis Carmel Medical Center /ID# 241867 | Haifa | Israel | 34362 | |
| 98 | Hadassah Medical Center-Hebrew University /ID# 241865 | Jerusalem | Israel | 91120 | |
| 99 | Meir Medical Center /ID# 241868 | Kfar Saba | Israel | 4428164 | |
| 100 | Galilee Medical Center /ID# 241870 | Nahariya | Israel | 2210001 | |
| 101 | Adan Hospital /ID# 229679 | Adan | Kuwait | ||
| 102 | Jahra Hospital /ID# 229671 | Jahra | Kuwait | 52700 | |
| 103 | Farwaniya Hospital /ID# 231445 | Kuwait City | Kuwait | 85000 | |
| 104 | RM Pharma Specialists S.A de C.V. /ID# 238816 | Mexico City | Ciudad De Mexico | Mexico | 03100 |
| 105 | Clinica de Investigacion en Reumatologia y Obesidad S.C. /ID# 238815 | Guadalajara | Jalisco | Mexico | 44650 |
| 106 | Centro de Estudios de Investigación Básica y Clínica, S.C. /ID# 238822 | Guadalajara | Jalisco | Mexico | 44690 |
| 107 | Desarrollos Biomedicos y Biotecnologicos /ID# 238818 | Monterrey | Nuevo Leon | Mexico | 64060 |
| 108 | Investigacion y Biomedicina de Chihuahua /ID# 238813 | Chihuahua | Mexico | 31000 | |
| 109 | Unidad de Investigacion de las Enfermedades Reumatologicas SA de CV /ID# 238824 | Mexico City | Mexico | 06090 | |
| 110 | Centro Especializado en Diabetes, Obesidad y Prevencion de Enfermedades Cardiova /ID# 238817 | Mexico City | Mexico | 11650 | |
| 111 | Consultorio Privado Jorge Rojas Serrano /Id# 239512 | Puebla | Mexico | 72550 | |
| 112 | Szpital Uniwersytecki nr 2 im. dr. Jana Biziela /ID# 243226 | Bydgoszcz | Kujawsko-pomorskie | Poland | 85-168 |
| 113 | Szpital Specjalistyczny im. J. Dietla w Krakowie /ID# 243228 | Cracow | Malopolskie | Poland | 31-121 |
| 114 | Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji /ID# 243232 | Warsaw | Mazowieckie | Poland | 02-637 |
| 115 | Ortopedyczno-Rehabilitacyjny Szpital Kliniczny im. Wiktora Degi /ID# 243225 | Poznan | Wielkopolskie | Poland | 61-545 |
| 116 | Jerzy Świerkot Indywidualna Specjalistyczna Praktyka Lekarska /ID# 244289 | Oława | Poland | 55-200 | |
| 117 | ChUZ Clinical Hospital RZD-Medicine /ID# 233185 | Ulan-Ude | Buryatiya, Respublika | Russian Federation | 670002 |
| 118 | Chelyabinsk Regional Clinical Hospital /ID# 244741 | Chelyabinsk | Chelyabinskaya Oblast | Russian Federation | 454087 |
| 119 | Regional Clinical Hospital of Kaliningrad region /ID# 238475 | Kaliningrad | Kaliningradskaya Oblast | Russian Federation | 236016 |
| 120 | LLC MC RevmaMed /ID# 238478 | Syktyvkar | Komi, Respublika | Russian Federation | 167031 |
| 121 | GBUZ RM "Mordovia Republican Central Clinical Hospital" /ID# 244738 | Saransk | Mordoviya, Respublika | Russian Federation | 430901 |
| 122 | Moscow Regional Research and Clinical Institute n.a. Vladimirskiy (MONIKI) /ID# 232510 | Moscow | Moskovskaya Oblast | Russian Federation | 129110 |
| 123 | Research Institute of Rheumatology named after V.A. Nasonova /ID# 238479 | Moscow | Moskva | Russian Federation | 115522 |
| 124 | Samara Regional Clinical Hospital n.a. V. D. Seredavin /ID# 231169 | Samara | Samarskaya Oblast | Russian Federation | 443095 |
| 125 | Nort-Western State Medical University n.a. Mechnikov /ID# 231172 | St. Petersburg | Sankt-Peterburg | Russian Federation | 193015 |
| 126 | City Clinical Hospital #52 /ID# 238477 | Moscow | Russian Federation | 123182 | |
| 127 | Orenburg State Medical University /ID# 233183 | Orenburg | Russian Federation | 460000 | |
| 128 | Republican hospital named after V.A. Baranov /ID# 231173 | Petrozavodsk | Russian Federation | 185019 | |
| 129 | Clinic of Samara State Medical University /ID# 241166 | Samara | Russian Federation | 443079 | |
| 130 | Clinical Rheumatologic Hospital No 25 /ID# 231171 | St. Petersburg | Russian Federation | 190068 | |
| 131 | Military Medical Academy n.a. Kirov /ID# 242363 | St. Petersburg | Russian Federation | 194044 | |
| 132 | Budgetary Institution of the Khanty-Mansiysk Autonomous Okrug-Yugra "Surgut Dist /ID# 242369 | Surgut | Russian Federation | 628400 | |
| 133 | Nebbiolo Clinical Research Center /ID# 231167 | Tomsk | Russian Federation | 634009 | |
| 134 | Ulyanovsk Regional Clinical Hospital /ID# 238334 | Ulyanovsk | Russian Federation | 432017 | |
| 135 | Yaroslavl State Medicat University /ID# 231168 | Yaroslavl | Russian Federation | 150000 | |
| 136 | Kantonsspital St. Gallen /ID# 230696 | St. Gallen | Sankt Gallen | Switzerland | 9007 |
| 137 | Rheumatologisches Versorgungszentrum Weinfelden /ID# 239435 | Weinfelden | Thurgau | Switzerland | 8570 |
| 138 | Mediclinic Airport Road Hospital /ID# 231227 | Abu Dhabi | United Arab Emirates | ||
| 139 | AlAin Hospital /ID# 233803 | Dubai | United Arab Emirates | ||
| 140 | Mediclinic City Hospital /ID# 231226 | Dubai | United Arab Emirates | ||
| 141 | Medica Uruguaya /ID# 231078 | Montevideo | Uruguay | 11600 |
Sponsors and Collaborators
- AbbVie
Investigators
- Study Director: ABBVIE INC., AbbVie
Study Documents (Full-Text)
None provided.More Information
Additional Information:
Publications
None provided.- P20-410